How do you approach patients with biochemical relapse of high-risk prostate cancer, with PSA doubling time less than 6 months?

Pt previously treated with radical prostatectomy and adjuvant radiotherapy. If recommending therapy, what is the role of concurrent abiraterone + ADT? The STAMPEDE study in NEJM July 2017 included some patients who were previously treated with radical surgery or radiotherapy and were relapsing with high-risk features (in men no longer receiving therapy, a PSA level >4 ng per milliliter with a doubling time of <6 months, a PSA level >20 ng per milliliter, nodal or metastatic relapse, or <12 months of total ADT with an interval of >12 months without treatment)